Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) (NCT03748953), a na phase 3 study. The primary outcome is Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS.

2. Clinical Question

The study description frames the broader objective as evaluating the long-term safety and tolerability of ixazomib maintenance therapy. The primary outcome listed in the record is not itself a direct summary of adverse events or a treatment-effect comparison. It records participants’ ECOG performance status at a specified follow-up point. Secondary outcomes listed include progression-free survival, overall survival, time to progression, time to next-line therapy, response-related outcomes, new primary malignancy, and change in EORTC QLQ-C30 global health status.

Because there is no randomized comparator in the stated design, this record cannot answer a comparative question about ixazomib versus another treatment. Its central statistical question is descriptive: what performance-status categories were recorded at Month 25 among the population covered by the outcome? The category counts needed to answer that question are not reported in the registry record.

3. Trial Design

This is a Phase 3, open-label, single-group study. The official title identifies it as a China continuation study of oral ixazomib maintenance after initial therapy in patients with newly diagnosed multiple myeloma who were not treated with stem cell transplantation. The registry lists multiple myeloma as the condition and ixazomib as the intervention. Allocation is recorded as NA, and masking as none.

The registry records enrollment of 37 and status as completed. The recorded start date is 2019-01-24, and the primary completion date is 2023-12-06. These dates describe the trial record; they do not establish the timing of every participant’s follow-up or the availability of each outcome. The study summary states that its purpose is to determine long-term safety and tolerability.

The ixazomib arm description specifies oral dosing on Days 1, 8, and 15. Participants began at 3 mg during Cycles 1 through 4, with escalation to 4 mg during Cycles 5 through 26 if the initial dose was tolerated. The recorded wording after this regimen is incomplete, so the complete stopping rule is not reported in the registry record.

The primary outcome is the number of participants categorized by ECOG performance status at Month 25. This is a descriptive outcome rather than a stated contrast between treatment groups. The record also lists 17 outcome measures, including survival, response, subsequent therapy, malignancy, and quality-of-life measures. It records zero analyses. The registry does not report a detailed statistical analysis plan, sample-size justification, or a full account of outcome-specific analysis populations. The safety information includes Ixazomib- and Placebo-labelled rows, but the record explicitly cautions that these are not a randomized comparison and are not like-for-like control groups.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Of the 31 participants who newly enrolled in this study, 10 (4 randomized to placebo and 6 to ixazomib) were enrolled before the implementation of Protocol Amendment 08, and 21 under the amendment, with all 21 receiving ixazomib as the study design was changed to a single-arm study. After Amendment 08, 2 of the 4 participants who were initially randomized to placebo crossed over to the ixazomib arm. As per planned analysis, these 4 participants were not included in the Efficacy Population.

Treatment Prior to Amendment 08

Reasons for not completing this period:

Treatment Post Amendment 08

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Ixazomib Safety Population (ISP) included all participants who received at least 1 dose of ixazomib. As prespecified in the SAP, the ISP contained only one arm i.e., Ixazomib (participants originally randomized to ixazomib + participants who were randomized to the placebo arm prior to implementation of Amendment 08 and who crossed over to ixazomib arm contributing data for this outcome measure from the time they initiated ixazomib onward), thus data is presented accordingly.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Efficacy Population included all participants who received ixazomib treatment for the duration of their study participation. As prespecified in the statistical analysis plan (SAP), the Efficacy Population contained only one arm i.e., Ixazomib (data for the participants who received placebo before Protocol Amendment 8 was not collected per statistical analysis plan), thus data is presented accordingly.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS, measured over Month 25.

The primary endpoint counts participants according to ECOG performance-status category at Month 25. ECOG status is used to describe physical functioning. In the registry’s definitions, grade 0 represents being fully active without restriction; grade 1 indicates restriction in strenuous activity while remaining ambulatory and able to do light or sedentary work; and grade 2 describes someone ambulatory and capable of self-care but unable to work, and up and about for more than 50% of waking hours. Grade 3 describes limited self-care, grade 4 complete disability with confinement to bed or chair for more than 50% of waking hours, and grade 5 death. The record says only categories with non-zero values were reported.

As a count outcome, this endpoint describes how many participants fall into each reported category. It does not, by itself, quantify change from baseline, establish why a participant has a given status, or compare ixazomib with a control treatment. ECOG status is used in clinical research to characterize functional condition in a standardized way, allowing readers to understand the distribution of reported status at a specified assessment time.

The category-specific counts at Month 25 are not reported in the registry record. Consequently, the outcome’s definition is available, but its observed distribution cannot be described from the registry information. The record also does not report details about handling participants without an assessment at Month 25.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods need to be interpreted in light of the question each outcome is designed to answer. In this study, the primary outcome is a count of participants categorized by ECOG performance status at Month 25. It is therefore a descriptive categorical outcome. The record does not report an estimated treatment contrast for this endpoint, and a single-group design does not provide a randomized between-treatment contrast for it.

What does a count outcome tell the reader?

A count states how many participants were recorded in a category. Counts are useful for showing the observed distribution of a categorical measure, especially when categories have clinically distinct meanings. Here, ECOG grades describe levels of physical functioning, from fully active to dead. The record says that only categories with non-zero values were reported. That convention means that an omitted category should not automatically be treated as a missing value; according to the outcome definition, zero-value categories were not listed. However, the category counts themselves are not reported in the registry record, so the distribution cannot be reconstructed.

Counts need a population and an assessment time to be interpretable. The listed time is Month 25. The safety population description says it includes participants who received at least 1 dose of ixazomib, but a complete population description for every analysis is not reported in the registry record. Nor does the record state how missing Month 25 assessments were handled. A reader cannot assume that the participants assessed at that time necessarily match the enrolled population.

Why does the design matter?

In general, random allocation helps make groups comparable on average, while masking can reduce some forms of assessment or reporting bias. This study is recorded as single-group, with allocation NA and masking none. The primary outcome is thus best understood as a description of status in the study population, not as an estimate of how ixazomib compares with an alternative. The Ixazomib- and Placebo-labelled safety rows do not change that interpretation: the registry cautions that the rows are not a like-for-like control comparison.

In general, a control group can help distinguish changes associated with an intervention from changes that might occur over time or from other influences. Without a valid comparison group, observed outcomes cannot be attributed to the intervention solely on the basis of this record. Open-label conduct can also affect outcomes that involve judgment or participant reporting. The record does not provide enough detail to assess the extent of any such influence on ECOG assessment or quality-of-life outcomes.

How should uncertainty be understood?

In general, a confidence interval expresses a range of values compatible with the observed data under the statistical model used. Its width reflects precision: a wider interval indicates greater uncertainty about the estimate. A p-value, when used, describes how compatible the observed data are with a specified null hypothesis under a model; it is not a measure of clinical importance or proof of causation. The registry information does not report a confidence interval or p-value for the primary endpoint. Since the category counts are also absent, no uncertainty estimate can be interpreted for that outcome.

For counts or proportions, precision depends in part on how many observations contribute to the estimate and on the distribution of those observations. For time-to-event outcomes, the number and timing of events and the follow-up available affect precision. These are general statistical principles; the registry does not report the data needed to assess precision for the listed secondary outcomes.

What does over-dispersion mean in general?

Over-dispersion occurs when observed variation is greater than a statistical model expects. It matters because a model that understates variability can produce uncertainty estimates that are too narrow. Count outcomes can sometimes show over-dispersion, depending on the data-generating process. The registry does not report a model for the primary count endpoint or diagnostics for over-dispersion. There is therefore no basis to say that over-dispersion was assessed or to describe its effect on an analysis in this study.

What can the planning illustrations establish?

The registry’s planning assumptions describe illustrations based on an observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation; the effect to detect is a stated fraction of the observed effect. For time-to-event outcomes, the described planning quantity is total events, while other outcomes use participants per arm. These are planning illustrations, not observed power and not a description of the trial’s own design. The record does not report the trial’s sample-size justification or a detailed account of its original statistical plan. Planning calculations cannot substitute for the missing Month 25 endpoint results, and their assumptions should not be mistaken for evidence that the study was designed or analyzed in that way.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 17 outcome measures, including survival outcomes, response-related outcomes, time to next-line therapy, new primary malignancy, and quality of life. When a study examines multiple outcomes or multiple comparisons, the chance of at least one apparently notable result can increase. Statistical approaches to multiplicity can adjust interpretation or control a specified error rate. The registry record does not report whether any multiplicity adjustment was planned or applied. It also records zero analyses, so the posted record does not provide a set of analysis results from which to assess how multiple outcomes were handled.

The record identifies the primary outcome as ECOG performance-status categories at Month 25, but the category counts are not reported in the registry record. It does not describe imputation, exclusion, or other handling of missing Month 25 assessments. Missing-data methods matter because participants with unrecorded outcomes may differ from those with observed outcomes. Without a stated method and information about missingness, the potential effect of missing assessments on the endpoint cannot be evaluated.

The safety population is described as including all participants who received at least 1 dose of ixazomib. The record does not give a complete analysis-population definition for each listed outcome or report how participants were handled across all analyses. The safety rows labelled Ixazomib and Placebo are explicitly not a like-for-like control comparison. Their counts should be read descriptively, not as a prespecified randomized analysis.

These omissions do not establish that a method was or was not used outside the registry information; they mean that the method is not reported in the registry record. In particular, the detailed statistical analysis plan, outcome-specific missing-data handling, and multiplicity approach are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: covid-19 (5.7%), cardiac failure congestive (2.9%), cataract (2.9%), chest discomfort (2.9%), cholelithiasis (2.9%).

The registry reports serious adverse events for 11 of 35 participants in the Ixazomib row and 0 of 4 in the Placebo row. Other adverse events are reported for 33 of 35 and 4 of 4, respectively. Deaths are listed as 1 and 0. These figures describe the records in those labelled groups. The registry cautions that the groups are not a like-for-like control comparison, so their counts should not be interpreted as a randomized estimate of relative safety.

The serious-event terms listed are COVID-19 at 5.7%, and cardiac failure congestive, cataract, chest discomfort, cholelithiasis, and pneumonia at 2.9% each. These percentages are quoted as recorded. The denominator and the detailed event-level rules for these term percentages are not reported in the registry record, so they should not be reverse-engineered into counts.

In general, serious adverse events are a category distinguished by seriousness criteria, not simply by how often an event occurs. An event being recorded during a study does not by itself show that the intervention caused it. The registry information does not establish causation for each event. The counts are useful as descriptive safety information, but design limitations and the absence of a comparable control group constrain comparative interpretation.

12. What the Result Does, and Does Not, Mean

The registry record establishes that this was a completed Phase 3, open-label, single-group study of ixazomib maintenance after initial therapy in participants with newly diagnosed multiple myeloma who were not treated with stem cell transplantation. It identifies the primary outcome as the number of participants in ECOG performance-status categories at Month 25 and provides the category definitions. It also lists adverse-event counts for Ixazomib- and Placebo-labelled rows and several serious-event terms with percentages.

Those details do not answer whether ixazomib changed performance status, prolonged survival, or affected quality of life. The Month 25 category counts are not reported in the registry record, and outcome-specific results for the listed secondary measures are not included in the registry record for interpretation. No treatment-effect estimate or uncertainty interval for the primary endpoint is reported. The design is single-group, so the record does not supply a randomized comparison that could isolate an effect of ixazomib from other influences.

The safety counts likewise do not demonstrate that an event was caused by treatment or establish a comparative safety difference. The registry specifically warns that the Ixazomib and Placebo rows are not a like-for-like control comparison. The serious-event terms and percentages are descriptive, and the denominator for those percentages is not reported in the registry record.

More generally, a statistical result describes data under a particular design, population, outcome definition, and analysis method. If the analysis plan, missing-data handling, and uncertainty estimates are not reported, readers cannot fully assess robustness or precision. The registry’s planning assumptions are illustrations and should not be treated as observed power or as results from a comparative trial. The sound interpretation is limited to what is recorded: the study’s design, its endpoint definition, and the stated safety counts, alongside substantial gaps in reported outcome results and analysis detail.

13. Why This Trial Matters Statistically

This trial is statistically notable because its primary endpoint and its stated study purpose address different aspects of the record. The stated purpose is long-term safety and tolerability, while the primary outcome is a Month 25 count of participants across ECOG performance-status categories. That distinction matters when interpreting what a reported endpoint could establish: a functional-status distribution is not, by itself, a comprehensive summary of safety or tolerability.

The single-group design is also central. It supports descriptive reporting of outcomes in the study population, but it does not provide a randomized comparison for estimating a treatment contrast. The safety record includes rows labelled Ixazomib and Placebo, yet the registry explicitly cautions that these are not like-for-like control groups. Careful interpretation avoids treating those rows as though random allocation had made them directly comparable.

The record also illustrates why an outcome definition alone is not enough for statistical interpretation. The ECOG categories and assessment time are described, but the observed category counts are not reported in the registry record. Without those values, readers cannot examine the endpoint distribution or assess its precision. The record lists many secondary outcomes and records zero analyses, while multiplicity methods, missing-data handling, and a detailed statistical plan are not reported.

Finally, the planning assumptions are distinct from the observed study evidence. Planning illustrations based on an observed effect do not constitute observed power, and they do not replace the trial’s actual endpoint results. Separating design, measurement, analysis, and reported data helps prevent descriptive safety counts or planning calculations from being mistaken for comparative evidence.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting the primary outcome is that the Month 25 ECOG category counts are not reported in the registry record. Although the outcome definition explains the categories and says only non-zero categories were reported, the observed distribution is unavailable. The record also does not report missing-assessment handling, so the effect of absent Month 25 observations cannot be evaluated.

The single-group, open-label design limits causal and comparative interpretation. Allocation is listed as NA and masking as none. The safety rows labelled Ixazomib and Placebo do not supply a valid randomized comparison; the registry explicitly cautions that they are not like-for-like control groups. Thus, the reported safety counts should not be read as estimates of relative risk or evidence that an event was caused by treatment.

The arm description gives a dosing schedule and describes escalation if the initial dose was tolerated, but its final stopping-condition wording is incomplete. The record does not report a complete statistical analysis plan, sample-size justification, multiplicity procedure, or outcome-specific missing-data method. Although 17 outcome measures are listed, the registry records zero analyses, and results for the secondary outcomes are not reported in the registry record.

The serious-event term percentages are reported without a denominator in the information available for interpretation. These percentages therefore should not be converted into inferred counts. More broadly, the posted information does not include confidence intervals or other measures of precision for the primary endpoint. These limitations leave the record useful for understanding the study’s design and selected safety reporting, but insufficient for a full assessment of outcome distributions, uncertainty, or comparative effects.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) — NCT03748953.
• Registry record last updated 2025-03-21; status last verified 2025-03.
• Results first posted 2025-03-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The record describes NCT03748953, a completed Phase 3, open-label, single-group study of oral ixazomib maintenance after initial therapy in participants with newly diagnosed multiple myeloma who were not treated with stem cell transplantation. Enrollment is recorded as 37. The recorded start date is 2019-01-24, and primary completion is dated 2023-12-06.

The primary outcome is a count of participants by ECOG performance-status category at Month 25. Category-specific results are not reported in the registry record. The registry lists 17 outcome measures and records zero analyses. Its safety information reports serious and other adverse-event counts and deaths for Ixazomib- and Placebo-labelled rows, while warning that these are not a like-for-like control comparison. Detailed statistical methods, missing-data handling, and multiplicity procedures are not reported in the registry record.